Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Mexico City
Clinical trial register · Mexico

Clinical Trials in Mexico City, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1585 matching records held by the registry are in this view. Synced 12 Oct 2026, 03:18 UTC
1585
Studies in scope
all four open statuses
715
Recruiting now
open to new participants
254
Lead sponsors
across recruiting studies
Top sites
Mexico City 17 Monterrey 15 Guadalajara 14 Mérida 8 Chihuahua City 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Mexico City

17 of 1585 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Chihuahua City, Benito Juárez, Mexico City, San Luis Potosí City
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Mexico City
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Mexico City
2025-06-23
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Chihuahua City, Guadalajara, Mexico City, Monterrey
2024-10-09
Recruiting
Novartis Pharmaceuticals
Phase 3
550
León, Guadalajara, Mexico City, Morelia, Mérida, México
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Mexico City, Huxquilucan
2024-03-12
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Guadalajara, Mexico City, Culiacán, Mérida, México
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
288
León, Guadalajara, Mexico City, Morelia, Mérida, México
2023-04-21
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
León, Actopan, Guadalajara, Gustavo Adolfo Madero, Mexico City, Tlalpan, Cuernavaca, Monterrey
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Mexico City, Monterrey
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
95
Mexico City
2022-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Chihuahua City, Mexico City, Querétaro
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Guadalajara, Mexico City, Monterrey, Tlalnepantla, Mérida, Acapulco, Aguascalientes, Chihuahua City
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Mexico City
2021-10-05
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Mexico City, Chihuahua City
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Mexico City, Distrito Federal
2013-07-26
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-mexico/city/mexico-city

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,585 studies in total at the last sync on 12 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Mexico City that also match the filters currently applied.

How many clinical trials are recruiting in Mexico City?

7 of the 17 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mexico City), 17 studies
PhaseStudiesRecruitingShare
Phase 315588.2%
Phase 2115.9%
Phase 2/3115.9%

Most active sponsors

Lead sponsors with the most studies (Mexico City)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals177
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.